PetVivo Sets Fiscal Fourth Quarter 2025 Conference Call for Monday, June 30 at 5:00 p.m. ET
Rhea-AI Summary
PetVivo Holdings (OTCQB: PETV), a biomedical company focused on therapeutic medical devices for animals, has scheduled its fiscal fourth quarter and full year 2025 earnings conference call for Monday, June 30, 2025, at 5:00 p.m. ET.
The company will release its financial results for the period ended March 31, 2025, before the conference call. Management will host a presentation followed by a Q&A session. Investors can access the call through a toll-free dial-in number or webcast, with a replay available afterward through the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, PETV declined 2.53%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MINNEAPOLIS, MN, US, June 26, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, will hold a conference call on Monday, June 30, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal fourth quarter and year ended March 31, 2025. The financial results will be issued in a press release prior to the call.
PetVivo management will host the presentation, followed by a question-and-answer period.
Date: Monday, June 30, 2025
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Toll-free dial-in number: +1 253 205 0468
Conference ID: 83424004566
Passcode: 352845
Webcast (live and replay): click here
A replay of the webcast will be available through the same link following the conference call.
The conference call webcast replay will also be available via a link in the Investors section of the company’s website at petvivo.com/investors.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
When is PetVivo's (PETV) Q4 2025 earnings call?
How can investors access PetVivo's (PETV) Q4 2025 earnings call?
Where can I find the replay of PetVivo's (PETV) Q4 2025 earnings call?
What period will PetVivo's (PETV) earnings report cover?
